文献速递前列腺增生与排尿功能障碍

可穿戴设备经皮胫神经刺激治疗膀胱过度活动症的疗效与安全性

Efficacy and safety of tibial nerve stimulation using a wearable device for overactive bladder.
PubMed 文献 · BJU Int · 2024-03-11

这项多中心、前瞻性、单盲、随机临床试验评估了可穿戴智能手机控制的可充电经皮胫神经刺激(TTNS)设备治疗膀胱过度活动症(OAB)的疗效与安全性。主要疗效终点为治疗4周后24小时排尿次数较基线的变化,刺激组在FAS中平均变化为-3.5次(标准差2.9),假刺激组为-0.6次(标准差2.4)(P < 0.01)。结论认为该无创神经调节技术有效且安全,但需未来研究确认长期疗效。

要点

  • 刺激组4周后24小时排尿次数较基线平均减少3.5次,假刺激组减少0.6次(P < 0.01)。
  • 两组尿急评分/次、每日夜尿次数和OABSS无显著差异。
  • 未报告设备相关严重不良事件。

核心结论

  • 使用新型便携式TTNS设备的无创神经调节技术对治疗OAB有效且安全,其便利性和易维护性使其成为新的潜在家庭治疗模式,但需未来研究确认长期疗效。

研究设计与样本

  • 多中心、前瞻性、单盲、随机临床试验,纳入有OAB症状的合格患者,随机分配至刺激组或假刺激组。

主要发现

  • 在全分析集(FAS)中,刺激组和假刺激组4周时24小时排尿次数平均(标准差)变化分别为-3.5(2.9)和-0.6(2.4)(P < 0.01)。
  • 在符合方案集(PPS)中,刺激组和假刺激组4周时24小时排尿次数平均(标准差)变化分别为-3.5(2.9)和-0.4(2.3)(P < 0.01)。
  • 在FAS和PPS中,4周时每次排尿量均显著改善(P = 0.01和P = 0.02)。
  • 在FAS中,PPBC改善接近显著性(P = 0.05),而在PPS中显著(P = 0.02)。
  • 在FAS和PPS中,两组4周时AUA-SI-QoL均显著改善(P < 0.01和P < 0.01),而两组间尿急评分/次、每日夜尿次数或OABSS无显著差异;未报告设备相关严重不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需未来研究确认其长期疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of a wearable, smartphone-controlled, rechargeable transcutaneous tibial nerve stimulation (TTNS) device in patients with overactive bladder (OAB). PATIENTS AND METHODS: This multicentre, prospective, single-blind, randomised clinical trial included eligible patients with OAB symptoms who were randomly assigned to the stimulation group or sham group. The primary efficacy outcome was change from baseline in voiding frequency/24 h after 4 weeks of treatment. The secondary efficacy outcomes included changes in bladder diary outcomes (urgency score/void, nocturia episodes/day, micturition volume/void, and incontinence episodes/day), questionnaires on Overactive Bladder Symptom Score (OABSS), Patient Perception of Bladder Condition (PPBC), and American Urological Association Symptom Index Quality of Life Score (AUA-SI-QoL) at baseline and after 4 weeks of treatment. Device-related adverse events (AEs) were also evaluated. RESULTS: In the full analysis set (FAS), the mean (sd) change of voiding frequency/24 h in the stimulation group and sham group at 4 weeks were -3.5 (2.9) and -0.6 (2.4), respectively (P < 0.01). Similar results were obtained in the per-protocol set (PPS): -3.5 (2.9) vs -0.4 (2.3) (P < 0.01). In the FAS and PPS, micturition volume/void significantly improved at 4 weeks (P = 0.01 and P = 0.02). PPBC improvement almost reached significance in the FAS (P = 0.05), while it was significant in the PPS (P = 0.02). In the FAS and PPS, AUA-SI-QoL significantly improved at 4 weeks in the two groups (P < 0.01 and P < 0.01), whereas there were no significant differences in urgency score/void, nocturia episodes/day or OABSS between the groups. Also, no device-related serious AEs were reported. CONCLUSIONS: The non-invasive neuromodulation technique using the novel ambulatory TTNS device is effective and safe for treating OAB. Its convenience and easy maintenance make it a new potential home-based treatment modality. Future studies are warranted to confirm its longer-term efficacy.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Liao L, Li X, Chong T, et al. Efficacy and safety of tibial nerve stimulation using a wearable device for overactive bladder. BJU Int. 2024. PMID: 38468422. doi:10.1111/bju.16330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。